Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Kedudukan dalam Saham #14765
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Harga Saham
$16.85
Disegerakkan terakhir: 2023-07-07
Modal Pasaran
$393.50M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CH
Perdagangan VectivBio Holding AG (VECT)

Kategori

Nisbah P/S bagi VectivBio Holding AG (VECT)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini VectivBio Holding AG, nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk VectivBio Holding AG dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.95 -
US
12.19 -
NL
3.75 -
AU
24.99 -
US
- -
CH